Protein farnesyl transferase inhibitors
AssigneeBristol-Myers Squibb Company
InventorsDinesh V. Patel, Scott A. Biller, Eric M. Gordon
Life of this patent
Estimating the term…
Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsDinesh V. Patel, Scott A. Biller, Eric M. Gordon
Estimating the term…
Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein: X is --ONR.sup.1 C(O)--, --N(OR.sup.1)C(O)--, --NR.sup.1 C(O)--, --C(O)NR.sup.1 --, --NR.sup.1 S(O.sub.2)--, --C(O)O--, --OC(O)--, --O--, --NR.sup.1 -- or --(S)q; Y and Z are each independently --CO.sub.2 R.sup.2, --SO.sub.3 R.sup.2 or --P(O)(OR.sup.2)(OR.sup.3); R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenylene or aryl; R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen, alkyl, aryl or aralkyl; m and n are each independently 0 or an integer from 1 to 5; p is 0 or 1; and q is an integer from 1 to 2.
A compound of the formula ##STR61## or an enantiomer, diastereomer, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
Dependencies are inferred from the claim text.